Company / R&D Expense
Niagen Bioscience, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$6.3M
FY2025
5-year range
$3.4M / $6.3M
FY2021-FY2025
Trend
+27.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 4 consecutive years, from $3M in FY2021 to $6M in FY2025.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of +7.4%.
Improved from $5M to $6M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +18.2%
- 5-Year CAGR
- +7.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Niagen Bioscience, Inc.'s r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +7.4%, indicating consistent growth.
- In FY2025, r&d expense increased 27.7% year-over-year.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.3M | +27.7% |
| FY2024 | $5.0M | +2.7% |
| FY2023 | $4.8M | +25.9% |
| FY2022 | $3.8M | +12.2% |
| FY2021 | $3.4M | -22.7% |
| FY2020 | $4.4M | +0.0% |
| FY2019 | $4.4M | +10.3% |
| FY2018 | $4.0M | +0.0% |
| FY2017 | $4.0M | +58.8% |
| FY2016 | $2.5M | +182.9% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026